Background Although survival outcomes of multiple myeloma (MM) have improved with the
development of new and effective agents, infection remains the major cause of morbidity …

Fluoroquinolone is recommended as a prophylactic antibiotic for high-risk patients with
profound neutropenia. We previously reported that multiple myeloma (MM) patients who …

Background Myeloma causes profound immunodeficiency and recurrent, serious infections.
Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of …

Multiple myeloma (MM) is a malignancy of clonal plasma cells, resulting in an increased
production of ineffective immunoglobulins with suppression of non-involved …

Abstract Abstract 3017 Introduction: Multiple myeloma (MM) is a malignancy of clonal
plasma cells with resulting in an increase production of ineffective immunoglobulins with …

Objective Ascertain the benefit of prophylactic antibiotics for patients with newly diagnosed
multiple myeloma (MM), given that clinical trials evaluating this have had conflicting results …

Background. Infections represent a major cause of toxicity in newly diagnosed multiple
myeloma (NDMM) patients, and their incidence is higher during the first 4 months of therapy …

Abstract Background TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) was a
randomised, double-blind, placebo-controlled multi-centre phase III clinical trial assessing …

Background: Multiple myeloma is a cancer of plasma cells that is associated with severe
immunodeficiency and increased numbers of bacterial infections. The Tackling Early …

Introduction. Multiple myeloma (MM) represents a population with an increased risk of
developing infection up to 10-fold if compared with controls. Moreover, patients treated with …